SCHEMBL2750299

SCHEMBL2750299

O=C(O)c1cccnc1Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
KDM5B Q9UGL1 1/20 0.51
SRD5A2 P31213 1/20 0.49
ASPH Q12797 2/20 0.48
KDM8 Q8N371 2/20 0.48
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP3A4 P08684 2/20 0.46
MEN1 O00255 1/20 0.46
GMNN O75496 1/20 0.46
TTR P02766 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
UGT1A1 P22309 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2749287 0.85 ALDH1A1 (0.55) KDM4CALDH1A1LMNATDP1CYP3A4
SCHEMBL15738996 0.84 KMT2A (0.53) ALDH1A1LMNATDP1CYP3A4CYP1A2
SCHEMBL258223 0.83 ALDH1A1 (0.55) KDM5AKDM4CKDM5BALDH1A1LMNA
SCHEMBL2749763 0.82 DHODH (0.58) KDM5AKDM4CKDM5BLMNATDP1
SCHEMBL12984306 0.82 KCNK2 (0.46) ALDH1A1LMNATDP1CYP3A4CYP2C9
SCHEMBL2129407 0.81 SMN1; SMN2 (0.59) SRD5A2ALDH1A1LMNATDP1CYP3A4
SCHEMBL8314979 0.77 SMN1; SMN2 (0.46) ALDH1A1LMNATDP1CYP3A4CYP2C9
Salicylic Acid SCHEMBL810603 0.77 ALDH1A1 (0.56) KDM4CALDH1A1LMNATDP1CYP3A4
SCHEMBL2129607 0.76 L3MBTL1 (0.49) ALDH1A1LMNATDP1MEN1KMT2A
SCHEMBL17784620 0.75 NAPRT (0.53) ALDH1A1LMNATDP1CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586755-B2 Substituted nicotinamides as KCNQ2/3 modulators Grünenthal GmbH (DE) 2013-11-19 US disclosed
US-20120184550-A1 SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2012-07-19 US disclosed
US-8178684-B2 Substituted nicotinamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2012-05-15 US disclosed
US-20100234429-A1 SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184550-A1 SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS KCNQ2, KCNQ1, KCNQ3 KDM5A 1827/4885KDM4C 1022/4885KDM5B 1763/4885
US-20100234429-A1 SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS KCNQ1, KCNQ2, KCNQ3 KDM5A 1092/4885KDM4C 827/4885KDM5B 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.